Guardion Health Sciences, Inc. (GHSI)
USD 3.22
(0.0%)
USD 3.22
(0.0%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 2.67 Million USD | -14.18% |
| 2022 | 3.11 Million USD | 748.38% |
| 2021 | 367.69 Thousand USD | -4.49% |
| 2020 | 384.97 Thousand USD | 23.81% |
| 2019 | 310.94 Thousand USD | -13.14% |
| 2018 | 357.99 Thousand USD | 131.37% |
| 2017 | 154.73 Thousand USD | 251.67% |
| 2016 | 43.99 Thousand USD | 43.96% |
| 2015 | 30.56 Thousand USD | 26.15% |
| 2014 | 24.22 Thousand USD | -74.16% |
| 2013 | 93.76 Thousand USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 2.13 Million USD | -20.28% |
| 2024 Q2 | 77.79 Thousand USD | -96.35% |
| 2023 Q4 | 2.67 Million USD | 9.24% |
| 2023 Q2 | 2.51 Million USD | -17.9% |
| 2023 FY | 2.67 Million USD | -14.18% |
| 2023 Q3 | 2.45 Million USD | -2.48% |
| 2023 Q1 | 3.06 Million USD | -1.88% |
| 2022 Q2 | 1.7 Million USD | 107.89% |
| 2022 Q1 | 822.32 Thousand USD | 123.65% |
| 2022 FY | 3.11 Million USD | 748.38% |
| 2022 Q4 | 3.11 Million USD | 59.73% |
| 2022 Q3 | 1.95 Million USD | 14.24% |
| 2021 Q2 | 956.25 Thousand USD | 231.43% |
| 2021 Q3 | 792.63 Thousand USD | -17.11% |
| 2021 Q4 | 367.69 Thousand USD | -53.61% |
| 2021 Q1 | 288.52 Thousand USD | -25.05% |
| 2021 FY | 367.69 Thousand USD | -4.49% |
| 2020 Q2 | 1.23 Million USD | 62.7% |
| 2020 Q3 | 1.28 Million USD | 3.98% |
| 2020 Q4 | 384.97 Thousand USD | -70.02% |
| 2020 Q1 | 759.08 Thousand USD | 144.13% |
| 2020 FY | 384.97 Thousand USD | 23.81% |
| 2019 Q3 | 320.35 Thousand USD | 0.52% |
| 2019 FY | 310.94 Thousand USD | -13.14% |
| 2019 Q4 | 310.94 Thousand USD | -2.94% |
| 2019 Q2 | 318.68 Thousand USD | 4.89% |
| 2019 Q1 | 303.81 Thousand USD | -15.13% |
| 2018 Q3 | 381.26 Thousand USD | -7.54% |
| 2018 Q4 | 357.99 Thousand USD | -6.1% |
| 2018 FY | 357.99 Thousand USD | 131.37% |
| 2018 Q1 | 182.91 Thousand USD | 18.22% |
| 2018 Q2 | 412.35 Thousand USD | 125.43% |
| 2017 Q2 | 108.3 Thousand USD | 116.5% |
| 2017 Q1 | 50.02 Thousand USD | 13.69% |
| 2017 FY | 154.73 Thousand USD | 251.67% |
| 2017 Q4 | 154.73 Thousand USD | -13.09% |
| 2017 Q3 | 178.03 Thousand USD | 64.38% |
| 2016 Q1 | - USD | -100.0% |
| 2016 FY | 43.99 Thousand USD | 43.96% |
| 2016 Q4 | 43.99 Thousand USD | -33.21% |
| 2016 Q3 | 65.87 Thousand USD | 94.57% |
| 2016 Q2 | 33.85 Thousand USD | 0.0% |
| 2015 Q1 | - USD | -100.0% |
| 2015 Q4 | 30.56 Thousand USD | -20.28% |
| 2015 Q3 | 38.33 Thousand USD | 0.0% |
| 2015 FY | 30.56 Thousand USD | 26.15% |
| 2014 FY | 24.22 Thousand USD | -74.16% |
| 2014 Q4 | 24.22 Thousand USD | 0.0% |
| 2013 FY | 93.76 Thousand USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 111.19 Million USD | 97.592% |
| Aquestive Therapeutics, Inc. | 6.76 Million USD | 60.45% |
| Collegium Pharmaceutical, Inc. | 32.33 Million USD | 91.72% |
| Cosmos Health Inc. | 4.78 Million USD | 44.099% |
| Dynavax Technologies Corporation | 53.29 Million USD | 94.976% |
| Intra-Cellular Therapies, Inc. | 11.64 Million USD | 77.015% |
| Pacira BioSciences, Inc. | 104.35 Million USD | 97.435% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | 53.318% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | 53.318% |
| SCYNEXIS, Inc. | - USD | -Infinity% |
| Safety Shot Inc | 1.86 Million USD | -43.188% |
| China SXT Pharmaceuticals, Inc. | 809.75 Thousand USD | -230.607% |
| Alpha Teknova, Inc. | 11.59 Million USD | 76.91% |
| Bright Green Corporation | - USD | -Infinity% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | 95.92% |
| Embecta Corp. | 152.1 Million USD | 98.24% |
| PainReform Ltd. | - USD | -Infinity% |
| Journey Medical Corporation | 10.2 Million USD | 73.769% |
| Procaps Group, S.A. | 96.83 Million USD | 97.235% |
| Theratechnologies Inc. | 6.06 Million USD | 55.867% |
| Harrow Health, Inc. | 10.86 Million USD | 75.365% |
| Sonoma Pharmaceuticals, Inc. | 2.71 Million USD | 1.541% |
| Biofrontera Inc. | 10.9 Million USD | 75.457% |
| DURECT Corporation | 2.21 Million USD | -20.645% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 96.542% |
| Cronos Group Inc. | 30.33 Million USD | 91.176% |
| OptiNose, Inc. | 8.05 Million USD | 66.752% |
| Ironwood Pharmaceuticals, Inc. | 1.00 USD | -267711100.0% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 5.69 Million USD | 53.025% |
| Organogenesis Holdings Inc. | 28.25 Million USD | 90.525% |
| Cumberland Pharmaceuticals Inc. | 4.6 Million USD | 41.92% |
| Radius Health, Inc. | 278.64 Million USD | 99.039% |
| Universe Pharmaceuticals INC | 3.34 Million USD | 19.925% |
| ProPhase Labs, Inc. | 3.84 Million USD | 30.302% |
| Phibro Animal Health Corporation | 265.91 Million USD | 98.993% |
| Procaps Group S.A. | 96.83 Million USD | 97.235% |
| Alvotech | 74.43 Million USD | 96.403% |
| TherapeuticsMD, Inc. | - USD | -Infinity% |
| Viatris Inc. | 3.46 Billion USD | 99.923% |
| Rockwell Medical, Inc. | 5.87 Million USD | 54.401% |
| Aytu BioPharma, Inc. | 12.63 Million USD | 78.809% |
| SIGA Technologies, Inc. | 64.21 Million USD | 95.831% |
| Tilray Brands, Inc. | 252.08 Million USD | 98.938% |
| Lifecore Biomedical, Inc. | 39.97 Million USD | 93.304% |
| Shineco, Inc. | 1.58 Million USD | -68.528% |
| PetIQ, Inc. | 159.3 Million USD | 98.32% |
| Regencell Bioscience Holdings Limited | -152.77 Thousand USD | 1852.289% |
| Incannex Healthcare Limited | -10.01 Million USD | 126.731% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | 93.01% |
| Alimera Sciences, Inc. | 1.87 Million USD | -42.475% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 37.68 Million USD | 92.896% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 1.61 Million USD | -66.24% |
| Clever Leaves Holdings Inc. | 4.48 Million USD | 40.283% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -952.522% |
| Avadel Pharmaceuticals plc | 10.38 Million USD | 74.209% |
| Hempacco Co., Inc. | 2.54 Million USD | -5.289% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 74.43 Million USD | 96.403% |
| Eagle Pharmaceuticals, Inc. | 47.79 Million USD | 94.399% |
| Lantheus Holdings, Inc. | 64.02 Million USD | 95.819% |
| Currenc Group, Inc. | 732.91 Thousand USD | -265.271% |
| Kamada Ltd. | 87.74 Million USD | 96.949% |
| Indivior PLC | 141.79 Million USD | 98.112% |
| Evoke Pharma, Inc. | 481.84 Thousand USD | -455.602% |
| Flora Growth Corp. | 8.5 Million USD | 68.534% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -952.522% |
| Evolus, Inc. | 10.99 Million USD | 75.658% |
| HUTCHMED (China) Limited | 50.25 Million USD | 94.673% |
| Amphastar Pharmaceuticals, Inc. | 105.83 Million USD | 97.47% |
| Akanda Corp. | 1.28 Million USD | -108.029% |